# Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis

> **NCT07366268** · NA · NOT_YET_RECRUITING · sponsor: **Assiut University** · enrollment: 36 (estimated)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Apremilast Nanoformula 0.3٪
- **DRUG:** betamethasone valerate 0.1% cream

## Key facts

- **NCT ID:** NCT07366268
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2027-05
- **Final completion:** 2028-03
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07366268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07366268, "Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07366268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*